These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1908353)

  • 1. Mouse Hepa-1 tumor is rejected by H-2Db-restricted CTL despite decreased MHC class I antigen expression.
    Nishimura MI; Ostrand-Rosenberg S
    Cell Immunol; 1991 Sep; 136(2):414-24. PubMed ID: 1908353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H-2Kb antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatoma.
    Nishimura MI; Stroynowski I; Hood L; Ostrand-Rosenberg S
    J Immunol; 1988 Dec; 141(12):4403-9. PubMed ID: 3264312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rejection of allogeneic tumor is not determined by host responses to MHC class I molecules and is mediated by CD4-CD8+ T lymphocytes that are not lytic for the tumor.
    Cole GA; Ostrand-Rosenberg S
    Cell Immunol; 1991 May; 134(2):480-90. PubMed ID: 1902400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of adenovirus 2 E3/19K glycoprotein on the expression of H-2Kb and H-2Db class I antigens and H-2Kb- and H-2Db-restricted SV40-specific CTL-mediated lysis.
    Tanaka Y; Tevethia SS
    Virology; 1988 Aug; 165(2):357-66. PubMed ID: 2970152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of simian virus 40 T antigen synthesized during viral lytic cycle in monkey kidney cells expressing mouse H-2Kb- and H-2Db-transfected genes by SV40-specific cytotoxic T lymphocytes leads to the abrogation of virus lytic cycle.
    Bates MP; Jennings SR; Tanaka Y; Tevethia MJ; Tevethia SS
    Virology; 1988 Jan; 162(1):197-205. PubMed ID: 2827378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogenous graft rejection pathways in class I major histocompatibility complex-disparate combinations and their differential susceptibility to immunomodulation induced by intravenous presensitization with relevant alloantigens.
    Kitagawa S; Iwata H; Sato S; Shimizu J; Hamaoka T; Fujiwara H
    J Exp Med; 1991 Sep; 174(3):571-81. PubMed ID: 1678775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4-CD8- T cell receptor alpha beta T cells: generation of an in vitro major histocompatibility complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection.
    Mieno M; Suto R; Obata Y; Udono H; Takahashi T; Shiku H; Nakayama E
    J Exp Med; 1991 Jul; 174(1):193-201. PubMed ID: 1905338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic T lymphocyte escape variants, induced mutations, and synthetic peptides define a dominant H-2Kb-restricted determinant in simian virus 40 tumor antigen.
    Mylin LM; Deckhut AM; Bonneau RH; Kierstead TD; Tevethia MJ; Simmons DT; Tevethi SS
    Virology; 1995 Apr; 208(1):159-72. PubMed ID: 11831696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes.
    Blake J; Johnston JV; Hellström KE; Marquardt H; Chen L
    J Exp Med; 1996 Jul; 184(1):121-30. PubMed ID: 8691125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4-negative cytotoxic T cells with a T cell receptor alpha/beta intermediate expression in CD8-deficient mice.
    Dalloul AH; Ngo K; Fung-Leung WP
    Eur J Immunol; 1996 Jan; 26(1):213-8. PubMed ID: 8566069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
    Yoshimura A; Shiku H; Nakayama E
    J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides.
    Carbone FR; Moore MW; Sheil JM; Bevan MJ
    J Exp Med; 1988 Jun; 167(6):1767-79. PubMed ID: 2455012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The non-classical MHC class I molecule Qa-1(b) inhibits classical MHC class I-restricted cytotoxicity of cytotoxic T lymphocytes.
    Lohwasser S; Kubota A; Salcedo M; Lian RH; Takei F
    Int Immunol; 2001 Mar; 13(3):321-7. PubMed ID: 11222501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y; Mayumi H; Eto M; Nomoto K
    J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular basis of skin allograft rejection across a class I major histocompatibility barrier in mice depleted of CD8+ T cells in vivo.
    Rosenberg AS; Munitz TI; Maniero TG; Singer A
    J Exp Med; 1991 Jun; 173(6):1463-71. PubMed ID: 1674524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The specificity of H-2-restricted cytotoxic T lymphocytes directed to AKR/Gross leukemia virus-induced tumors. I. Isolation of a selectively resistant variant tumor subclone.
    Green WR
    Eur J Immunol; 1983 Nov; 13(11):863-70. PubMed ID: 6196206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.
    Stober D; Jomantaite I; Schirmbeck R; Reimann J
    J Immunol; 2003 Mar; 170(5):2540-8. PubMed ID: 12594280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role for helper cell subpopulations in a genetically controlled cytolytic T lymphocyte response to the H-2Db antigen.
    French DL; Plate JM
    J Immunol; 1985 Jul; 135(1):39-46. PubMed ID: 3158704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T lymphocyte precursor cells specific for the major histocompatibility complex class I-like antigen, Qa-2, require CD4+ T cells to become primed in vivo and to differentiate into effector cells in vitro.
    Muraoka S
    Eur J Immunol; 1991 Sep; 21(9):2095-103. PubMed ID: 1679712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological characterization of tumor-rejection antigens on ultraviolet-light-induced tumors originating in the CB6F1 mouse.
    Kitajima T; Iwashiro M; Kuribayashi K; Imamura S
    Cancer Immunol Immunother; 1994 Jun; 38(6):372-8. PubMed ID: 8205558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.